Annual report pursuant to Section 13 and 15(d)

General (Details)

v3.20.1
General (Details) - USD ($)
$ in Thousands
1 Months Ended 12 Months Ended
Oct. 28, 2019
Dec. 31, 2019
Dec. 31, 2018
Dec. 31, 2017
Recapitalization transaction, percentage 100.00%      
Issued of common stock   22,862,835 2,307,871  
Total consideration from merger   $ 60,100    
Restricted cash and cash equivalent   72,410 $ 8,693 $ 6,993
Short-term deposits   $ 10,003 $ 31,055  
Risk factors, description   Operations for more than 12 months from the date of issuance of these financial statements and sufficient to fund its operations necessary to continue development activities of its current proposed products.    
BiomX Israel [Member]        
Issued of common stock   15,069,058    
Percentage issued to former shareholders of subsidiary in the merger 65.00%